title: Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g).
abstract: Milling is a usual process used in the course of drug formulation, which however may change the physical nature of the end product. The diversity of the transformations of organic compounds upon milling has been widely demonstrated in the pharmaceutical literature. However, no effort has still been devoted to study the correlation between the nature of the transformation and the milling conditions. Results clarifying such transformations are shortly reviewed with special attention paid to the temperature of milling. The importance of the position of the glass transition temperature compared with that of milling is demonstrated. It is shown that decreasing the milling temperature leads to an increase of the amorphization tendency whereas milling above T(g) can produce a crystal-to-crystal transformation between polymorphic varieties. These observations contradict the usual suggestion that milling transforms the physical state only by a heating effect which induces a local melting. Equilibrium thermodynamics does not seem appropriate for describing the process. The driven alloys concept offers a more rational framework to interpret the effect of the milling temperature. Other results are also presented, which demonstrate the possibility for milling to form low temperature solid-state alloys that offer new promising ways to stabilize amorphous molecular solids.
authors: Laboratoire de Dynamique et Structure des Matériaux Moléculaires, UMR, CNRS 8024, University of LILLE1, Bat P5 - 59655 Villeneuve d'Ascq Cedex, France. marc.descamps@univ-lille1.fr
authors: M
authors: M
authors: Descamps
authors: J F
authors: JF
authors: Willart
authors: E
authors: E
authors: Dudognon
authors: V
authors: V
authors: Caron
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry*; D019819:Budesonide / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D003460:Crystallization; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D007785:Lactose / Q000737:chemistry; D008353:Mannitol / Q000737:chemistry; D008956:Models, Chemical; D013012:Sorbitol / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods*; D044366:Transition Temperature; D014199:Trehalose / Q000737:chemistry; D014867:Water / Q000737:chemistry
chemical_list: D000893:Anti-Inflammatory Agents; D005079:Excipients; D014867:Water; D008353:Mannitol; D013012:Sorbitol; D019819:Budesonide; D014199:Trehalose; D007785:Lactose